

Cover Story
By Matthew Bin Han Ong
In the next few weeks, FDA will announce its decision on Novartis's Zarxio, a granulocyte-colony stimulating factor biosimilar to Amgen's Neupogen.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- Christine Lovly to lead City of Hope’s new national thoracic oncology program
- FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence - Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA
- Smoldering multiple myeloma: Rethinking the waiting game
- Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director













